Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology

Autores
Sookoian, Silvia Cristina; Pirola, Carlos José
Año de publicación
2020
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome.
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Materia
COMPLEX TRAITS
GENETICS
NONALCOHOLIC FATTY LIVER DISEASE
PRECISION MEDICINE
STEATOHEPATITIS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/117144

id CONICETDig_98a43c4a18a2260a19393aa6232c6e74
oai_identifier_str oai:ri.conicet.gov.ar:11336/117144
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biologySookoian, Silvia CristinaPirola, Carlos JoséCOMPLEX TRAITSGENETICSNONALCOHOLIC FATTY LIVER DISEASEPRECISION MEDICINESTEATOHEPATITIShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome.Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaKorean Association for the Study of the Liver2020-09-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/117144Sookoian, Silvia Cristina; Pirola, Carlos José; Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology; Korean Association for the Study of the Liver; Clinical and Molecular Hepatology; 26; 4; 10-9-2020; 461-4752287-27282287-285XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.e-cmh.org/journal/view.php?doi=10.3350/cmh.2020.0136info:eu-repo/semantics/altIdentifier/doi/10.3350/cmh.2020.0136info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:06:53Zoai:ri.conicet.gov.ar:11336/117144instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:06:53.769CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
title Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
spellingShingle Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
Sookoian, Silvia Cristina
COMPLEX TRAITS
GENETICS
NONALCOHOLIC FATTY LIVER DISEASE
PRECISION MEDICINE
STEATOHEPATITIS
title_short Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
title_full Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
title_fullStr Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
title_full_unstemmed Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
title_sort Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
dc.creator.none.fl_str_mv Sookoian, Silvia Cristina
Pirola, Carlos José
author Sookoian, Silvia Cristina
author_facet Sookoian, Silvia Cristina
Pirola, Carlos José
author_role author
author2 Pirola, Carlos José
author2_role author
dc.subject.none.fl_str_mv COMPLEX TRAITS
GENETICS
NONALCOHOLIC FATTY LIVER DISEASE
PRECISION MEDICINE
STEATOHEPATITIS
topic COMPLEX TRAITS
GENETICS
NONALCOHOLIC FATTY LIVER DISEASE
PRECISION MEDICINE
STEATOHEPATITIS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome.
Fil: Sookoian, Silvia Cristina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Pirola, Carlos José. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
description Despite more than two decades of extensive research focusing on nonalcoholic fatty liver disease (NAFLD), no approved therapy for steatohepatitis—the severe histological form of the disease—presently exists. More importantly, new drugs and small molecules with diverse molecular targets on the pathways of hepatocyte injury, inflammation, and fibrosis cannot achieve the primary efficacy endpoints. Precision medicine can potentially overcome this issue, as it is founded on extensive knowledge of the druggable genome/proteome. Hence, this review summarizes significant trends and developments in precision medicine with a particular focus on new potential therapeutic discoveries modeled via systems biology approaches. In addition, we computed and simulated the potential utility of the NAFLD polygenic risk score, which could be conceptually very advantageous not only for early disease detection but also for implementing actionable measures. Incomplete knowledge of the druggable NAFLD genome severely impedes the drug discovery process and limits the likelihood of identifying robust and safe drug candidates. Thus, we close this article with some insights into emerging disciplines, such as chemical genetics, that may accelerate accurate identification of the druggable NAFLD genome/proteome.
publishDate 2020
dc.date.none.fl_str_mv 2020-09-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/117144
Sookoian, Silvia Cristina; Pirola, Carlos José; Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology; Korean Association for the Study of the Liver; Clinical and Molecular Hepatology; 26; 4; 10-9-2020; 461-475
2287-2728
2287-285X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/117144
identifier_str_mv Sookoian, Silvia Cristina; Pirola, Carlos José; Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology; Korean Association for the Study of the Liver; Clinical and Molecular Hepatology; 26; 4; 10-9-2020; 461-475
2287-2728
2287-285X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://www.e-cmh.org/journal/view.php?doi=10.3350/cmh.2020.0136
info:eu-repo/semantics/altIdentifier/doi/10.3350/cmh.2020.0136
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Korean Association for the Study of the Liver
publisher.none.fl_str_mv Korean Association for the Study of the Liver
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269978921795584
score 13.13397